Indication for use Control of vasculitic activity in rare trial of ANCA positive systemic necrotising vasculitis Two indications have been used. systemic necrotising vasculitis failing to failing to respond to corticosteroids and All qualifying patients will only receive 6 months respond to corticosteroids and cytotoxic cytotoxic immunosuppression treatment. immunosuppression. A second indication supports the further Relapse in ANCA positive systemic necrotising treatment of responders who relapse following vasculitis resistant following response to Ig cessation of Ig therapy. Different qualifying and therapy review criteria will (A)
Indication for use Control of vasculitic activity in rare of systemic necrotising vasculitis failing to respond to corticosteroids and cytotoxic immunosuppression. ANCA positive systemic necrotising vasculitis failing to respond to corticosteroids and cytotoxic immunosuppression Relapse in ANCA positive systemic necrotising vasculitis resistant following response to Ig therapy Two indications have been used. All qualifying patients will only receive 6 months treatment. A second indication supports the further treatment of responders who relapse following cessation of Ig therapy. Different qualifying and review criteria will (A) trial
anti-neutrophil-cytoplasmic-antibody%28anca%29.DOCX